Thrombin, Factor IXa, Factor Xa, Factor XIa, Factor XIIa (FIIa or IIa, FIXa, FXa, FXIa, FXIIa)

Thrombin, factor IXa, factor Xa, factor XIa, and factor XIIa are serine protease enzymes that orchestrate the sequential steps of blood coagulation following vascular injury. Their catalytic actions—starting from activation of factor XIIa, proceeding through the activation of factor XIa and factor IXa, and culminating in the generation of factor Xa and thrombin—lead to the rapid formation of a fibrin clot, essential for hemostasis. These enzymes are prominent drug targets for anticoagulants used to prevent or treat thrombotic diseases, including deep vein thrombosis and atrial fibrillation. Drugs acting on these targets include direct inhibitors, such as rivaroxaban and dabigatran, and indirect inhibitors, such as heparin. Monitoring their activity is critical to balance the efficacy and safety of anticoagulant therapy, as excessive inhibition increases bleeding risk, while insufficient inhibition may result in clot formation[1][2][3][4].

Other names

Prothrombin (inactive precursor)Christmas factor (inactive precursor)Stuart–Prower factor (inactive precursor)Plasma thromboplastin antecedent (inactive precursor)Hageman factor (inactive precursor)Activated forms are often referred with the "a" suffix after the Roman numeral, e.g. "Xa"

Inhibition of enzymatic activity: Most drugs block the protease active site, preventing downstream activation of clotting proteins. Indirect inhibition via antithrombin: Heparin and related drugs increase antithrombin activity, leading to inactivation of several factors, including IIa, Xa, IXa, XIa, XIIa. Interference with complex formation: Some cofactors or drugs disrupt the formation of enzyme complexes necessary for clot propagation.